Bradley EH, Herrin J, Mattera JA, Holmboe ES, Wang Y, Frederick P, Roumanis SA, Radford MJ, Krumholz HM
Clinical trial averages show semaglutide users losing 10-15% of body weight over 68 weeks, and tirzepatide users losing 15-22% of body weight over 72 weeks
Monitoring frequency should be individualized based on patient risk factors and concurrent medications
Seek urgent medical attention if you experience severe unrelenting abdominal pain, persistent vomiting with inability to tolerate fluids, complete inability to pass stools or wind for over 24 hours, vomiting blood, passing black tarry stools, or fever with abdominal pain
The governing arithmetic is always the same three steps: vial mg BAC mL = concentration (mg/mL)